THALOMID Drug Patent Profile

When do Thalomid patents expire, and when can generic versions of Thalomid launch?

Thalomid is a drug marketed by Bristol-myers and is included in one NDA.

The generic ingredient in THALOMID is thalidomide. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the thalidomide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Thalomid

A generic version of THALOMID was approved as thalidomide by NATCO on April 24^th, 2026.

Summary for THALOMID

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	109
Clinical Trials:	73
Patent Applications:	5,002
Drug Prices:	Drug price information for THALOMID
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for THALOMID
What excipients (inactive ingredients) are in THALOMID?	THALOMID excipients list
DailyMed Link:	THALOMID at DailyMed

See drug prices for THALOMID

Recent Clinical Trials for THALOMID

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Emory University	Phase 2
Janssen Scientific Affairs, LLC	Phase 2
Nanfang Hospital of Southern Medical University	Phase 3

See all THALOMID clinical trials

Pharmacology for THALOMID

Physiological Effect

Decreased Immunologically Active Molecule Activity

Paragraph IV (Patent) Challenges for THALOMID

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
THALOMID	Capsules	thalidomide	150 mg	020785	1	2014-02-03
THALOMID	Capsules	thalidomide	50 mg and 100 mg	020785	1	2006-12-18
THALOMID	Capsules	thalidomide	200 mg	020785	1	2006-09-25

US Patents and Regulatory Information for THALOMID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-001	Jul 16, 1998	AB	RX	Yes	No
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-003	Jan 17, 2003	AB	RX	Yes	Yes
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-002	Jan 17, 2003	AB	RX	Yes	No
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-004	Jan 10, 2007		RX	Yes	No

Expired US Patents for THALOMID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-004	Jan 10, 2007
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-001	Jul 16, 1998
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-003	Jan 17, 2003
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-001	Jul 16, 1998
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-002	Jan 17, 2003
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-001	Jul 16, 1998
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-003	Jan 17, 2003

EU/EMA Drug Approvals for THALOMID

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Bristol-Myers Squibb Pharma EEIG	Thalidomide BMS (previously Thalidomide Celgene)	thalidomide	EMEA/H/C/000823Thalidomide BMS in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy., , Thalidomide BMS is prescribed and dispensed according to the Thalidomide Celgene Pregnancy Prevention Programme (see section 4.4).,	Authorised	no	no	no	2008-04-16
Lipomed GmbH	Thalidomide Lipomed	thalidomide	EMEA/H/C/005715Thalidomide Lipomed in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy.Thalidomide Lipomed is prescribed and dispensed in accordance with the Thalidomide Lipomed Pregnancy Prevention Programme (see section 4.4).	Authorised	no	no	no	2022-09-19

International Patents for THALOMID

See the table below for patents covering THALOMID around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	218865
Austria	304356
Australia	6248694
Australia	676722
Brazil	9400764
Canada	2157288	METHODES ET COMPOSITIONS POUR L'INHIBITION DE L'ANGIOGENESE (METHODS AND COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS)
Canada	2342974	METHODES ET COMPOSITIONS POUR L'INHIBITION DE L'ANGIOGENESE (METHODS AND COMPOSITIONS FOR INHIBITION OF ANGIOGENESIS)

Supplementary Protection Certificates for THALOMID

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0620232	08C0036	France		PRODUCT NAME: THALIDOMIDE; REGISTRATION NO/DATE: EU/1/08/443/001 20080416
0688211	91471	Luxembourg		91471, EXPIRES: 20190224
0688211	CA 2008 00034	Denmark
0688211	300358	Netherlands		300358, 20140224, EXPIRES: 20190223
0688211	SPC025/2008	Ireland		SPC025/2008: 20090811, EXPIRES: 20190223
0688211	SPC/GB08/039	United Kingdom		PRODUCT NAME: THALIDOMIDE (INTERNATIONAL NON-PROPRIETARY NAME) 2-(2,6-DIOXOPIPERIDIN-3-YL) ISOINDOLINE-1,3-DIONE (SYSTEMATIC (IUPAC) NAME); REGISTERED: UK EU/1/08/443/001 20080416
0688211	C300358	Netherlands		PRODUCT NAME: THALIDOMIDE; REGISTRATION NO/DATE: EU/1/08/443/001 20080416

Last updated: July 29, 2026

Thalomid (thalidomide) market dynamics and financial trajectory: sales trends, exclusivity, competition, and future revenue exposure

Thalomid (thalidomide) remains a core branded hematology franchise in the US and select ex-US markets, sustained by ongoing use in multiple myeloma treatment lines and by a long-lived IP and regulatory footprint for branded supply. Market dynamics over the last decade have been shaped by (1) gradual erosion from branded and authorized generic competition in some jurisdictions, (2) penetration and regimen evolution within multiple myeloma that keeps thalidomide relevant in cost-sensitive settings, and (3) class competition from newer oral immunomodulatory drugs and monoclonal antibody regimens that have capped growth rather than allowing major expansion.

On the financial trajectory side, the branded peak-to-decline pattern has stabilized into lower, steadier demand tied to myeloma incidence, regional formulary access, and treatment-cycle persistence. Near-term revenue exposure is driven less by a single “hard stop” event and more by continued generic share shifts and distribution pressure, offset only partially by brand stickiness where supply reliability and REMS-adjacent distribution controls matter.

Why does Thalomid still sell in multiple myeloma despite generics and newer drugs?

What drives ongoing clinician demand and payer coverage

Thalomid’s persistence is anchored to:

• Established clinical positioning as an immunomodulatory therapy in multiple myeloma, including earlier-line and combination regimens where dosing familiarity and total regimen affordability support use.
• Strong embedded prescribing behavior in markets where newer agents are priced higher and formularies emphasize value.
• Treatment-cycle continuity, where switching across mechanisms may not be optimal for some patients due to comorbidity, tolerability history, or reimbursement dynamics.

How regimen evolution changed Thalomid’s market role

The broader multiple myeloma standard of care has shifted toward combination regimens incorporating next-generation immunomodulatory agents and proteasome inhibitors, and increasingly toward antibody-based regimens in later lines. That evolution:

• Limits incremental growth for thalidomide-based regimens
• Keeps thalidomide in the platform “toolbox,” with use concentrating where cost and access favor it

What competition looks like at the class level

Thalomid faces two overlapping competitive fronts:

1. Within-class competition from later-generation immunomodulatory drugs (IMiDs), which are often preferred when label, tolerance, and payer incentives align.
2. Supply competition from authorized and non-authorized generics depending on jurisdiction and enforcement, which compresses branded pricing where barriers are lower.

How does Thalomid exclusivity and patent life affect generic substitution risk?

What is the exclusivity framework (US) that matters for generic entry

Generic substitution risk in the US is governed by:

• Patent expiration and last relevant listed Orange Book patents covering the drug substance and key approved conditions of use or formulations.
• Hatch-Waxman Paragraph IV litigation for abbreviated new drug applications (ANDAs).
• Practical constraints on thalidomide distribution, including the drug’s controlled distribution and safety program structure, which affects how quickly generic products can be scaled.

How long does Thalomid face “must-watch” timelines?

Thalomid’s major exclusivity and initial compound-era protection has passed, so the current market is shaped by:

• Remaining patent “islands” that may protect specific combinations, methods of use, or manufacturing/formulation details where Orange Book listings still exist.
• Settlement-driven launch calendars when Paragraph IV disputes culminate in negotiated entry dates.

What generic entry risks exist by product category

• Substance-level generic risk: Higher where no enforceable product-specific barriers remain for the approved dosage form and strength.
• Method-of-use risk: Higher if claims track specific dosing schedules or therapeutic combinations that remain enforceable.
• Formulation risk: Lower for simple dosage forms where generic equivalence is easier to establish, but higher where protective manufacturing or formulation details exist.

What is the Orange Book status of Thalomid and which patents still matter?

Orange Book listing mechanics that drive market outcomes

Even after broad compound-patent expiration, the Orange Book can continue to constrain generic approval if:

• Patents are listed for a drug product listed by FDA.
• The ANDA filer must certify to each listed patent (Paragraph I-IV or carve-outs where applicable).
• Litigation stays or forfeiture provisions apply, depending on the ANDA and certification outcomes.

What to monitor in the Orange Book for Thalomid

Key items that typically determine ongoing branded protection and launch timing:

• Patent numbers tied to specific strengths (thalidomide capsules across strengths).
• Method-of-use or indication-linked patents.
• Manufacturing and process patents that could be argued as requiring design-around changes.

Which companies compete with Thalomid and how do their market strategies differ?

Competitive landscape: branded vs generics

• Branded Thalomid: Maintains share where clinician preference, payer contracts, or supply reliability support continued use.
• Generics/authorized generics: Gain share through price discounting and formulary placement, especially when branded pricing becomes non-competitive.

Distribution and safety-program execution as a commercial lever

Thalidomide’s controlled distribution requirements influence:

• Speed to scale for new entrants
• Contracting outcomes with wholesalers and specialty pharmacies
• Practical “availability” differences that can tilt payer behavior toward products perceived as consistently available

How did Thalomid’s sales trend over time and what are the key financial inflection points?

Expected sales pattern for a mature thalidomide brand

For mature products with passed compound exclusivity, the typical financial trajectory is:

• High initial revenue under strong exclusivity
• Mid-to-late decline as generics take share
• Stabilization as remaining market segments and supply-chain constraints keep demand for the branded product

What usually creates inflection points in thalidomide brands

• Entry of authorized generics or enforceable-launch-date generic products
• Shifts in myeloma treatment standards that reallocate demand across lines of therapy
• Contracting changes tied to wholesaler formularies and rebate adjustments
• Supply or REMS-adjacent operational constraints that temporarily affect availability

Revenue drivers that still matter

• Patient population size and growth in diagnosed multiple myeloma
• Persistence on thalidomide-based regimens in cost-sensitive settings
• Concentration of use in earlier lines in some geographies and in relapsed settings where affordability and clinical familiarity drive continued prescribing

How does Thalomid pricing and reimbursement pressure shape its financial trajectory?

Pricing dynamics

Branded revenue typically declines as:

• Generic discounts become the new benchmark
• PBM and payer contracting moves to value-based tiering
• Health systems demand lower acquisition costs due to budget compression and therapy substitution

Rebate and formulary mechanics

Thalomid’s net revenue is sensitive to:

• Contract intensity in large systems
• Changes in payer policies for immunomodulatory drug selection
• Movement of myeloma regimens from thalidomide combinations to alternatives that offer better evidence for specific populations

What settlements or litigation have historically influenced Thalomid generic launch timing?

Why litigation outcomes matter even after compound expiration

Once major patents expire, remaining listed patents can still create:

• ANDA launch delays via automatic stays or negotiated settlement terms
• Delayed market entry for non-authorized generics
• Prolonged price pressure for the branded product until the next entry wave

How to map litigation to financial outcomes

For a mature franchise, the money usually moves on:

• The first credible generic entry wave in a high-value market
• Any later waves tied to remaining formulation or method-of-use patents
• Settlement dates that can cause “cliff” drops when the next product becomes available

How does Thalomid compare with newer multiple myeloma therapies in market position?

Competitive differentiation

New oral agents and antibody-based regimens tend to score higher on:

• Convenience profiles and trial outcomes in some settings
• Perceived line-of-therapy optimization

Thalomid’s differentiation is often:

• Affordability and access in value-focused environments
• Long-standing clinical integration into regimen ecosystems

Where Thalomid still has a structural advantage

• Regions and payer systems where total regimen cost matters as much as incremental efficacy
• Patient segments where tolerability history makes switching across classes less attractive

What regulatory factors affect Thalomid market access and supply?

FDA safety program and distribution constraints

Thalomid’s distribution is controlled through its risk management structure. This affects market dynamics by:

• Influencing supply-chain readiness for brand and generic products
• Raising operational compliance requirements that can slow entrants
• Increasing the cost of scaling distribution, which can reduce price competition intensity early in a launch cycle

How risk management translates to commercial reality

In practice, even when patents permit entry, entrants still must:

• Establish compliant distribution
• Maintain reliable supply in specialty settings
• Sustain REMS program performance through ongoing monitoring and controls

What generic entry scenarios could reduce Thalomid share further?

Scenario map: where share loss is most likely

• Scenario 1: broad formulary substitution in major payers, driven by incremental generic availability and contracting that shifts immunomodulatory preference.
• Scenario 2: intensified rebate pressure for branded share preservation, leading to lower net prices and reduced profitability even if unit volume holds.
• Scenario 3: supply normalization where controlled distribution barriers weaken and entrants scale faster, accelerating price erosion.

Scenario 4: indication or regimen changes

If treatment guidelines further favor newer agents in most payer-covered lines, thalidomide demand can decline structurally, not just competitively.

Key Takeaways

• Thalomid’s market dynamics are dominated by mature-drug forces: generic substitution and payer contracting pressure, offset by entrenched use in multiple myeloma and supply-chain execution under controlled distribution.
• The financial trajectory is consistent with a peak-to-decline pattern that stabilizes into lower growth with periodic revenue shocks tied to new generic waves and contracting changes.
• Exclusivity is less about a single imminent expiration and more about remaining Orange Book patent islands and settlement-driven launch timing.
• Near-term revenue exposure depends on the pace of generic share gains and on how quickly payer formularies reallocate myeloma regimens away from thalidomide toward newer IMiDs and antibody-based regimens.
• Competitive moat for branded Thalomid is operational reliability and contracting stickiness rather than chemical exclusivity.

FAQs

1. How do thalidomide risk management requirements affect the speed of generic launches?
2. What drives payer preference for thalidomide-based regimens in cost-sensitive multiple myeloma populations?
3. Which multiple myeloma treatment line shifts most directly reduce thalidomide demand?
4. How do settlement terms in Hatch-Waxman disputes typically change Thalomid revenue forecasts?
5. What operational or supply constraints most often create short-term Thalomid availability swings?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. Thalomid (thalidomide) prescribing information and safety risk management materials. U.S. Food and Drug Administration.
3. FDA. Hatch-Waxman Drug Product and ANDA guidance documents relevant to patent certifications and generic approval timelines. U.S. Food and Drug Administration.